- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Bausch Health Companies Inc(BHC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BHC
11/13/2026: BHC (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Bausch Health Companies Inc is a global specialty pharmaceutical and medical device enterprise operating across gastroenterology, eye health, and dermatology. The company exhibits solid operational strengths through established franchises like Xifaxan and Bausch + Lomb, supported by steady organic revenue growth. Its primary investment story centers on capturing market share from new product launches while unlocking asset value. However, significant risks remain, including a heavy debt load, looming patent cliffs, and pricing pressures. The stock suits risk-tolerant turnaround or momentum investors willing to monitor debt management and pipeline execution.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While key segments exhibit steady organic growth, total corporate growth is capped by debt service obligations. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience sharp upside momentum bursts following positive earnings beats or favorable litigation/regulatory updates. |
| Value investor | Mixed fit | The stock trades at low valuation multiples, but heavy balance sheet leverage introduces complex underlying risk. |
| Dividend investor | Weak fit | The company does not pay a common stock dividend, prioritizing cash flow for debt reduction. |
| Low-risk investor | Weak fit | High financial leverage and historical equity volatility render the stock unsuitable for low-risk mandates. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is prone to sharp swings driven by legal, debt-refinancing, and regulatory headlines. |
| Valuation risk | Medium / high | Enterprise value is heavily influenced by total debt obligations relative to operating earnings. |
| Competition risk (generic and branded pharmaceutical pressure) | High | Impending patent expirations threaten core product revenue streams with low-cost generic alternatives. |
| Business quality | Medium | Core operating franchises possess solid market share, but past financial restructuring impacts overall profile quality. |
| Dividend income | Low / none | No dividend distributions are currently paid to common shareholders. |
| Execution risk | Medium / high | Management must successfully balance pipeline execution with complex debt maturity walls. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.13B USD | Price to earnings Ratio - | 1Y Target Price 8.4 |
Price to earnings Ratio - | 1Y Target Price 8.4 | ||
Volume (30-day avg) 3.8M shares | Beta 0.28 | 52 Weeks Range 4.33 - 9.04 | Updated Date 11/15/2026 |
52 Weeks Range 4.33 - 9.04 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.26 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -26.33% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Bausch + Lomb | Global sales of contact lenses, lens care solutions, surgical equipment, and ophthalmic pharmaceuticals. | This is the company's largest revenue pillar, benefiting from steady demand in vision care. |
| Salix Pharmaceuticals | U.S. specialty gastroenterology drugs, most notably Xifaxan. | A high-margin profit engine driven by specialist gastrointestinal prescriptions. |
| Solta Medical | Global aesthetic devices including Thermage and Clear + Brilliant. | Provides exposure to cash-pay dermatology and aesthetic medical clinics. |
| International & Diversified Products | Branded pharmaceuticals, generics, and OTC lines outside the U.S., plus domestic neurology and dermatology. | Offers geographic and therapeutic diversification outside core pillars. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-28 | When After Market | Estimate 1.08 | Actual 1.77 |
Profitability
Profit Margin -7.57% | Operating Margin (TTM) 27.18% |
Management Effectiveness
Return on Assets (TTM) 7.22% | Return on Equity (TTM) -11040% |
Valuation
Trailing PE - | Forward PE 1.92 | Enterprise Value 21.35B | Price to Sales(TTM) 0.28 |
Enterprise Value 21.35B | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 1.92 | Enterprise Value to EBITDA 8.94 | Shares Outstanding 374.27M | Shares Floating 260.86M |
Shares Outstanding 374.27M | Shares Floating 260.86M | ||
Percent Insiders 11.24 | Percent Institutions 61.79 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

